Valsartan Actavis 160 mg Norge - norsk - Statens legemiddelverk

valsartan actavis 160 mg

actavis group ptc ehf - valsartan - tablett, filmdrasjert - 160 mg

Valsartan Actavis 40 mg Norge - norsk - Statens legemiddelverk

valsartan actavis 40 mg

actavis group ptc ehf - valsartan - tablett, filmdrasjert - 40 mg

Valsartan Actavis 80 mg Norge - norsk - Statens legemiddelverk

valsartan actavis 80 mg

actavis group ptc ehf - valsartan - tablett, filmdrasjert - 80 mg

Valsartan Actavis 320 mg Norge - norsk - Statens legemiddelverk

valsartan actavis 320 mg

actavis group ptc ehf - valsartan - tablett, filmdrasjert - 320 mg

Stabilised Ceretec - Norge - norsk - Statens legemiddelverk

stabilised ceretec -

ge healthcare as - kobolt(ii)kloridheksahydrat / eksametazim - preparasjonssett til radioaktive legemidler

Chromium [51Cr] EDTA Injection GE Healthcare 3.7 MBq/ ml Norge - norsk - Statens legemiddelverk

chromium [51cr] edta injection ge healthcare 3.7 mbq/ ml

ge healthcare ltd - krom (51cr) edetat - injeksjonsvæske, oppløsning - 3.7 mbq/ ml

Cancidas (previously Caspofungin MSD) Den europeiske union - norsk - EMA (European Medicines Agency)

cancidas (previously caspofungin msd)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika for systemisk bruk - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.